Pandemic's Impact on Child Cognitive, Emotional Well-Being Mixed
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Nov. 28, 2023 -- Pandemic exposure is associated with both positive and negative aspects of young children’s cognitive and emotional well-being, according to a study published online Nov. 16 in JAMA Network Open.
Katherine E. Finegold, from the University of Toronto, and colleagues examined associations of pandemic exposure with neurocognitive and socioemotional development at 24 (718 children) and 54 months of age (703 children) participating in the Ontario Birth Study (February 2018 to June 2022).
The researchers found that at 24 months of age, pandemic-exposed children had a reduced risk for problem-solving difficulties using cutoff scores (odds ratio, 0.33) and higher problem-solving (B, 3.93) compared with nonexposed children. However, pandemic-exposed children had a higher risk for personal-social difficulties using cutoff scores (odds ratio, 1.67) and continuous scores (B, −1.70) versus nonexposed children. Pandemic-exposed children had higher receptive vocabulary at 54 months of age (B, 3.16), visual memory (B, 5.95), and overall cognitive performance (B, 3.89) versus nonexposed children, with no differences in socioemotional development.
"These findings suggest that health care practitioners and educators may encounter a mix of pandemic-related outcomes among young children as they plan recovery efforts following the pandemic," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-11-29 00:32
Read more

- Miscommunication Between Health Workers Puts Patients At Risk Regularly
- Common Diabetes Drug Effective Against Knee Arthritis Pain
- FDA Announces Plan to Phase Out Some Animal Testing
- Advanced Biological Age Linked to Increased Risk for Incident Dementia
- Metabolic Syndrome Linked to Increased Risk for Young-Onset Dementia
- Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions